Rating Rationale
February 23, 2023 | Mumbai
Centenial Surgical Suture Limited
Ratings downgraded to 'CRISIL BBB-/Stable/CRISIL A3'
 
Rating Action
Total Bank Loan Facilities RatedRs.20 Crore
Long Term RatingCRISIL BBB-/Stable (Downgraded from 'CRISIL BBB/Negative')
Short Term RatingCRISIL A3 (Downgraded from 'CRISIL A3+')
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Rating has downgraded its rating on the long-term bank facility of Centenial Surgical Suture Limited (CSSL) to 'CRISIL BBB-/Stable/CRISIL A3' from 'CRISIL BBB/Negative/CRISIL A3+'.

 

The downgrade reflects moderation of business risk profile of the company, mainly operating margin. Consequently, accruals have remained subdued. Company’s operating margin has been declining over past 3 years and is estimated at 8% for 9 months ended Dec 2022 of fiscal 2023 against 10-14% in past. Operating margin of company was mainly impacted on account of increase in raw material prices and limited ability to pass on to customers. Sustained improvement in operating margin while maintaining revenue growth to remain rating sensitivity factor.

 

The rating continues to reflect a moderate business risk profile backed by an established market position in the specialized Coronary Artery Bypass Graft (CABG) surgery segment, and a strong relationship with customers and suppliers. The ratings also factor in a comfortable financial risk profile. These strengths are partially offset by a modest scale, and working capital-intensive nature, of operations.

Key Rating Drivers & Detailed Description

Strengths:

Extensive experience of the promoters: The company has been manufacturing surgical sutures for more than 27 years. It specializes in absorbable and non-absorbable sutures used in CABG, where it has a healthy market share in India. The manufacturing facility is certified by ISO 9001:2015, ISO 13485:2016, WHO-GMP, ISO 45001:2018 and medical devices are in conformity to medical device directives 93/42/EEC, Medical Device Rules, 2017. The company has a strong track record in terms of quality and availability. It has maintained relationships with reputed customers such as Narayana Hospitals, Wockhardt Hospitals and Fortis Hospitals Ltd, among others, for more than 10 years.

 

Comfortable financial risk profile: Company has healthy financial risk profile with comfortable capital structure and robust debt protection metrics. Company has networth base of around Rs 30.19 crore as on March 31, 2022. Comfortable Debt protection metrics with interest coverage and net cash accruals to adjusted debt ratio of 2.35 times and 0.23 time in fiscal 2022. Moderate operating profits of 10.22%. The financial risk profile is expected to remain comfortable over the medium term on account of low debt and average profitability.

 

Weaknesses:

Modest scale amid dipping operating margin: Company has modest scale of operations indicated by revenue of Rs 44 crore in fiscal 2022. While it is expected to improve during fiscal 2023 it continues to remain modest. Company has done revenue of Rs XX crore for 9 months of fiscal 2023. Considering the size of the suture market, an increase in business scale would be limited and depend on the ability to control a larger share in the CABG suture market and compete in other segments. Further, operating margin has moderated to around 8% during the year on account of increase in raw material prices and limited ability to pass on to customers due to competitive market. Increase in scale while maintaining operating margin remains to be seen.

 

Working capital-intensive nature of operations: Company has sizeable working capital requirements as reflected by gross current assets of 439 days as on March 31, 2022 on back of increase in inventory to 297 days and elongated debtors' period (debtors of 160 days). The high debtor days are because payments from medical institutions are linked to timely disbursals by medical insurance companies.

Liquidity: Adequate

Liquidity is adequate. Net cash accrual is expected to be Rs.2.1 – 2.5 crore per fiscal over the medium term against Nil term debt obligations. Company has access to cash credit limit of Rs.15 crore, which has been utilized at an average of 56% during the 12 months ended December 2022. Net cash accrual and the unutilized bank limit should be sufficient to fund incremental working capital requirement. Company has no major capex plans over the medium term.

 

Current ratio are healthy at 2.2 times on March 31, 2022.Low gearing and moderate net worth support it’s financial flexibility, and provides the financial cushion available in case of any adverse conditions or downturn in the business.

Outlook: Stable

CRISIL Ratings believes company will continue to benefit from established market position in the specialized Coronary Artery Bypass Graft (CABG) surgery segment, and a strong relationship with customers and suppliers.

Rating Sensitivity factors

Upward factors

* Improved demand resulting in significant jump in revenue & operating margin of above 10% resulting in improved cash accruals.

* Significant improvement in working capital cycle and GCA days to come below 180 days.

 

Downward factors

* Further stretch in working capital cycle or higher than expected debt funded capex weaking financial risk profile and liquidity.

* Decline in operating margin below 6% range resulting in lower cash accrual

About the Company

Set up in 1995, CSSL is a publicly listed company that manufactures highly specialized absorbable and non-absorbable sutures (cardiovascular sutures and atraumatic needled sutures) that are primarily used in CABG surgeries, and other medical devices. It sells products under Centisorb, Centicryl, Centisynth, Centicryl Rapid, Centisilk, Centilene, Centibond, Centlon, and Centsteel brands. The company’s manufacturing facility is at Murbad in Thane, Maharashtra. The manufacturing facility is certified by ISO 9001:2015, ISO 13485:2016, WHO-GMP, ISO 45001:2018 and medical devices are in conformity to medical device directives 93/42/EEC, Medical Device Rules, 2017.

Key Financial Indicators

As on / for the period ended March 31

 

2022

2021

Operating income

Rs crore

44.22

36.47

Reported profit after tax

Rs crore

0.63

0.96

PAT margins

%

1.42

2.64

Adjusted Debt/Adjusted Net worth

Times

0.31

0.46

Interest coverage

Times

2.35

2.45

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN Name of
instrument
Date of
allotment
Coupon
rate (%)
Maturity
date
Issue size
(Rs crore)
Complexity 
levels
Rating assigned
with outlook
NA Bank Guarantee NA NA NA 0.25 NA CRISIL A3
NA Cash Credit NA NA NA 15 NA CRISIL BBB-/Stable
NA Letter of Credit NA NA NA 4 NA CRISIL A3
NA Proposed Long Term Bank Loan Facility NA NA NA 0.75 NA CRISIL BBB-/Stable
Annexure - Rating History for last 3 Years
  Current 2023 (History) 2022  2021  2020  Start of 2020
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 15.75 CRISIL BBB-/Stable   --   -- 30-11-21 CRISIL BBB/Negative 28-08-20 CRISIL BBB/Negative CRISIL BBB/Stable
Non-Fund Based Facilities ST 4.25 CRISIL A3   --   -- 30-11-21 CRISIL A3+ 28-08-20 CRISIL A3+ CRISIL A3+
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Rating
Bank Guarantee 0.25 CRISIL A3
Cash Credit 15 CRISIL BBB-/Stable
Letter of Credit 4 CRISIL A3
Proposed Long Term Bank Loan Facility 0.75 CRISIL BBB-/Stable
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Understanding CRISILs Ratings and Rating Scales
CRISILs Criteria for rating short term debt

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Jaya Mirpuri
Director
CRISIL Ratings Limited
D:+91 20 4018 1926
jaya.mirpuri@crisil.com


Rushabh Pramod Borkar
Team Leader
CRISIL Ratings Limited
D:+91 22 3342 3390
rushabh.borkar@crisil.com


ANIKET NAVALKISHOR RATHI
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
ANIKET.RATHI@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html